The DOI matches its Crossref record; 344 of the 344 references it cites were found in a registry or an index.
Anti-obesity drug discovery: advances and challenges
Open accessAbstract
Enormous progress has been made in the last half-century in the management of diseases closely integrated with excess body weight, such as hypertension, adult-onset diabetes and elevated cholesterol. However, the treatment of obesity itself has proven largely resistant to therapy, with anti-obesity medications (AOMs) often delivering insufficient efficacy and dubious safety. Here, we provide an overview of the history of AOM development, focusing on lessons learned and ongoing obstacles. Recent advances, including increased understanding of the molecular gut–brain communication, are inspiring the pursuit of next-generation AOMs that appear capable of safely achieving sizeable and sustained body weight loss. The development of therapies that are capable of safely achieving sizeable and sustained body weight loss has proved tremendously challenging. Here, Müller et al. provide an overview of the history of anti-obesity drug development, focusing on lessons learned, ongoing challenges and recent advances in the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The regulation of body weight is orchestrated primarily by the brain and adipose tissue (Figure 1), which constantly integrate information related to the body’s energetic state to adjust food intake, satiety and energy balance8,10.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Beyond its role in glucose metabolism, GLP-1 is known to possess cardio- and neuroprotective effects, reduce cellular apoptosis and inflammation, and modulate reward behavior and palatability8,55 (Figure 1).”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, despite appreciable weight loss of ~5-8% in the short term, such lifestyle interventions have only limited potential for sustained weight reduction, particularly when utilized as a stand-alone therapy8.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with this model is a battery of preclinical and clinical studies demonstrating that weight loss induced by GLP-1R agonism is enhanced when adjunctively administered with glucagon, GIP, amylin, CCK or FGF21, which can be achieved as co-therapy, or in a unimolecular polyagonist formulation8.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, most of these efforts have been plagued with significant adverse effects and/or limited efficacy which has resulted in the withdrawal and discontinued use for the majority of these medications [5].”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [5]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Genetics of Food Intake Self-Regulation in Childhood: Literature Review and Research Opportunities
Faith, M. S., Carnell, S., & Kral, T. V. E. (2013) · Human Heredity · doi:10.1159/000353879 · Cited by 7,601
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Brown Adipose Tissue: Function and Physiological Significance
CANNON, B., & NEDERGAARD, J. (2004) · Physiological Reviews · doi:10.1152/physrev.00015.2003 · Cited by 6,433
Cited by
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
Ng, M., Gakidou, E., Lo, J., Abate, Y. H., Abbafati, C., Abbas, N., Abbasian, M., Abd ElHafeez, S., Abdel-Rahman, W. M., Abd-Elsalam, S., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00355-1 · Cited by 1,151
“99,100 Access and cost are other key considerations.”
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., & Xu, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1161521 · Cited by 799
Contemporary medical, device, and surgical therapies for obesity in adults
Perdomo, C. M., Cohen, R. V., Sumithran, P., Clément, K., & Frühbeck, G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02403-5 · Cited by 738
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
Pati, S., Irfan, W., Jameel, A., Ahmed, S., & Shahid, R. K. (2023) · Cancers · doi:10.3390/cancers15020485 · Cited by 677
Metadata
- Authors
- Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D.
- Affiliations
- Helmholtz Munich (DE)
- Indiana University Bloomington (US)
- Corresponding author
- Müller, Timo D.
- DiMarchi, Richard D.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2021-11-23
- Volume
- 21
- Issue
- 3
- Pages
- 201-223
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC8609996
- OpenAlex
- W3217337816
- Semantic Scholar
- b0e07187edbb01228cee2a7f1f5884b1c6df014c
- Cited by
- 1,021
- References
- 343
- Citations by year
- 2026: 136 · 2025: 255 · 2024: 286 · 2023: 221 · 2022: 123
- FWCI
- 20.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Alexander von Humboldt-Stiftung
- Deutsche Forschungsgemeinschaft (TRR- 152, TRR296)
- Servier
- H2020 European Research Council (695054)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- anti-obesity drugs, obesity, drug development history, drug safety, sustained weight loss, gut-brain signaling, obesity pharmacotherapy
- MeSH terms
- Adult, Diabetes Mellitus, Type 2, Humans, Obesity, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-obesity drug discovery: advances and challenges. https://app.cochat.ai/papers/10.1038/s41573-021-00337-8
- The paper
- Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022). Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-021-00337-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.